Lansoprazol Stada

Lansoprazole, the active ingredient in Lansoprazol Stada, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is employed to manage conditions such as gastro‑esophageal reflux disease, duodenal ulcer, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome.

GNH USA supplies Lansoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for bulk and unit‑dose orders across multiple continents.

Lansoprazole, the active component of Lansoprazol Stada, acts on the gastric proton pump to lower acid secretion in several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Duodenal ulcer: facilitates ulcer healing by maintaining a less acidic gastric environment. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotics by suppressing gastric acid. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazol Stada may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Diarrhea - Abdominal pain - Nausea

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Low serum magnesium (hypomagnesemia) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Lansoprazol Stada, several precautionary measures should be considered to ensure safe use.

- Renal or hepatic impairment: assess function before initiating therapy and adjust duration as needed. - Elderly patients: monitor for increased risk of confusion, falls, and dehydration. - Discontinuation: avoid abrupt cessation after prolonged use; taper to reduce rebound acid hypersecretion. - Infection risk: be vigilant for signs of gastrointestinal infections, especially C. difficile. - Concomitant medications: review drugs that require acidic environment for absorption (e.g., ketoconazole, atazanavir). - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazol Stada can alter the pharmacokinetics of several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Clarithromycin: may increase lansoprazole levels, raising risk of toxicity. - Ketoconazole: reduced absorption of ketoconazole, compromising antifungal efficacy. - Atazanavir (and other HIV protease inhibitors): markedly decreased antiviral exposure. - Ritonavir‑boosted regimens: significant reduction in protease inhibitor concentrations.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum digoxin concentrations; monitor levels. - Methotrexate: reduced renal clearance; watch for toxicity. - Warfarin: potential enhancement of anticoagulant effect; check INR. - Phenytoin: decreased phenytoin levels; adjust dosage if needed.